Is Johnson & Johnson Stock a Buy Now?
Healthcare giant Johnson & Johnson (NYSE: JNJ) has a lot going its way. It is one of the largest and most recognizable companies in its industry, boasting a vast portfolio of products and a culture of innovation. However, Johnson & Johnson has also been dealing with a barrage of lawsuits alleging that its talc-based products gave customers cancer.
The company recently received more bad news on that front that sent its share price tumbling. Should investors take this opportunity to pick up the company's shares on the dip, or are Johnson & Johnson's legal troubles enough of a reason to avoid the stock?
First, we need some background to understand the latest developments in Johnson & Johnson's long battle against these cases. In 2021, the company created a subsidiary called LTL Management, which would become responsible for managing the legal claims against its cosmetic talc-based products. It then had the subsidiary file for bankruptcy protection to help manage the litigation and limit liability.
Source Fool.com
